Oric Pharmaceuticals, Inc.
ORIC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001796280
In the last 90 days, Oric Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Market capClose on Nov 13, 2026
- $814.7M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.52M in total
- 5
- 13F holdersQ2 2026, 0 vs. previous quarter
- 180
- 13F valueReported value at the end of Q2 2026
- $1.34B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$129.5M
- No comparable prior period
- Free cash flow, FY2025
- -$111.7M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.7M
- Shares sold short
- Change
- −4.69M
- −30.4% vs. previous
- Days to cover
- 4.80
- At average daily volume
Superinvestors holding ORIC, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Oric Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.2%
Oric Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 5,126,762
- Value
- $55.5M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Oric Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 21, 2026 (view filing)5:17 PM ET | Oct 20 | 1 day | Piscitelli DominicChief Financial Officer | SSale | −14.0K | $13.53 | −$189.4K | −16.7%69.8K after | 10b5-1 |
| Oct 2, 2026 (view filing)5:50 PM ET | Oct 1 | 1 day | Heyman Richard A.Director | SSale | −3.50K | $12.91 | −$45.2K | −8.4%38.3K after | 10b5-1 |
| Oct 2, 2026 (view filing)5:50 PM ET | Oct 1 | 1 day | Heyman Richard A.Director | SSale | −3.20K | $12.91 | −$41.3K | −1.5%203.5K after | 10b5-1 |
| Sep 29, 2026 (view filing)7:16 PM ET | Sep 28 | 1 day | Piscitelli DominicChief Financial Officer | SSale | −13.4K | $13.53 | −$181.3K | −16.1%69.8K after | 10b5-1 |
| Sep 25, 2026 (view filing)7:59 PM ET | Sep 24 | 1 day | Piscitelli DominicChief Financial Officer | SSale | −600 | $13.50 | −$8.10K | −0.9%69.8K after | 2 lots10b5-1 |
| Aug 28, 2026 (view filing)4:11 PM ET | Aug 26 | 2 days | Piscitelli DominicChief Financial Officer | SSale | −77.0K | $13.69 | −$1.05M | −52.4%69.8K after | 10b5-1 |
| Jul 28, 2026 (view filing)4:15 PM ET | Jul 24 | 4 days | Heyman Richard A.Director | SSale | −7.00K | $12.02 | −$84.1K | −15.5%38.3K after | 10b5-1 |
| Jul 28, 2026 (view filing)4:15 PM ET | Jul 24 | 4 days | Heyman Richard A.Director | SSale | −6.10K | $12.02 | −$73.3K | −2.9%206.7K after | 10b5-1 |
| Jul 8, 2026 (view filing)4:35 PM ET | Jul 6 | 2 days | Heyman Richard A.Director | SSale | −300 | $12.00 | −$3.60K | −0.1%212.8K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Piscitelli DominicChief Financial Officer | SSale | −52.0K | $13.51 | −$702.5K | −43.3%68.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 180 holdersThe largest institutional positions in Oric Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nextech Invest, Ltd. | 7,162,637 | $77.6M | 3.68% | 00.0% | Unchanged |
| BlackRock, Inc. | 6,823,973 | $73.9M | 0.00% | +839,421+14.0% | Added |
| EcoR1 Capital, LLC | 6,728,116 | $72.9M | 3.61% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 6,617,554 | $71.7M | 0.01% | +1,229,771+22.8% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 5,126,762 | $55.5M | 0.16% | −697,771−12.0% | Reduced |
| State Street Corp | 4,894,000 | $53.0M | 0.00% | +1,191,804+32.2% | Added |
| Sr One Capital Management, LP | 4,615,384 | $50.0M | 4.81% | +100,455+2.2% | Added |
| VR Adviser, LLC | 4,319,765 | $46.8M | 1.42% | 00.0% | Unchanged |
| NEA Management Company, LLC | 4,118,621 | $44.6M | 2.81% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 3,951,169 | $42.8M | 0.00% | +264,162+7.2% | Added |
Holders of 5% or more of ORIC
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Oric Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Nextech Crossover I GP S.a r.l. | 13G/A | 8.40%7.16M shares | – | Jul 7, 20233 filings | Aug 14, 2025 | SEC |
| Viking Global Investors LPSuperinvestorViking Global Investors | 13G/A | 7.80%8.26M shares | −2.19 ppfrom 9.99% | Jan 30, 20244 filings | May 15, 2026 | SEC |
| EcoR1 Capital, LLC | 13G | 6.90%6.73M shares | – | Feb 16, 20216 filings | Aug 5, 2025 | SEC |
| BlackRock, Inc. | 13G | 5.60%5.47M shares | +1.40 ppfrom 4.20% | Oct 22, 20244 filings | Jan 21, 2026 | SEC |
| Price T Rowe Associates Inc | 13G | 5.40%5.39M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |